Interlink is on track to assist at least 15 Italian companies using $1.4 million of catalytic funding to raise additional capital with a multiple of 12x, or a total of approximately $20 million in less than 15 months. The goal of the initiative is to support businesses that are engaged in the research, development, or manufacture of therapeutics, vaccines, medical equipment, and supplies to respond to COVID-19.
While setting up a traditional investment fund can be costly and time consuming, to work around these constraints and deliver during the crisis, Interlink created an innovative funding model to leverage capital from other sources to allow Italian companies to convert or expand their operations to respond in a timely manner to the COVID-19 pandemic. Catalytic funding is provided at a macro (i.e., a pool of capital) and micro level (i.e., directly to the companies). Examples of each include:
In the 6 months that Interlink has worked on this initiative, it has already raised over $16 million in the micro-level and $15 million in the macro-level fundraising, therefore increasing the possibility of funding above and beyond the 15 company mark and demonstrating the strength of this approach. Comments are closed.
|
|